We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
Read MoreHide Full Article
Key Takeaways
Amarin reports better-than-expected results on both fronts, with revenues rising 7% year over year.
Vascepa sales rose 6%, driven by higher partnered volumes and strong supply shipments to Recordati.
Cost cuts and restructuring reduced expenses, supporting positive cash flow and efficiency gains.
Amarin Corporation (AMRN - Free Report) incurred an adjusted loss of 9 cents per share for the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported an adjusted loss of 45 cents per share in the year-ago quarter. Adjusted loss per share excluded stock-based compensation expense and restructuring expense.
Total revenues in the quarter were $45.1 million, beating the Zacks Consensus Estimate of $42 million. Revenues increased 7% from the year-ago quarter’s level, driven by higher partnered sales volume.
Year to date, shares of Amarin have risen 2.4% against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
AMRN's Q1 Earnings in Detail
Amarin’s top line comprises product revenues from its sole marketed drug, Vascepa, along with licensing and royalty revenues. Vascepa is approved as an adjunct to diet for the treatment of severe hypertriglyceridemia and to reduce cardiovascular risk in patients with persistently elevated triglycerides on statin therapy for LDL-C.
Net product revenues from Vascepa in the first quarter were $43.3 million, up 6% year over year. This metric beat the Zacks Consensus Estimate of $39.5 million.
U.S. product revenues from Vascepa were $35.6 million, consistent with the prior-year period.
Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $4.9 million, decreasing 9% from the year-ago quarter. This was due to the company’s transition to a fully partnered model with Recordati in the European market. However, Vazkepa sales increased 113% sequentially.
Revenues in the Rest of the World were $2.8 million.
Licensing and royalty revenues came in at $1.8 million in the first quarter, increasing 84% on a year-over-year basis due to higher in-market sales generated by international sales partners.
Selling, general and administrative expenses (excluding stock-based compensation expense) declined 41.3% year over year to $19.4 million.
Research and development expenses (excluding stock-based compensation expense) totaled $4.1 million, decreasing 9% on a year-over-year basis.
Amarin ended the quarter with cash and investments of $307.8 million compared with $302.6 million as of Dec. 31, 2025, and remained debt-free.
AMRN's Recent Key Developments
In 2025, Amarin signed an exclusive, long-term licensing and supply agreement with Italy-based pharmaceutical company Recordati to commercialize Vazkepa across 59 European countries. Recordati has already begun commercial activities in 10 countries, including a launch in Italy in the fourth quarter of 2025, and plans to gradually expand distribution across additional European markets over the coming years.
Under this fully partnered ex-U.S. model, management expects improved cost efficiency and sustained positive cash flow in 2026. The company has already delivered positive cash flow for two consecutive quarters through the first quarter of 2026.
Per management, with the transition now complete, reported European revenues will solely comprise supply shipments made to Recordati going forward.
Amarin remains on track to realize approximately $70 million in annual cost savings under the global restructuring program and has incurred the majority of the restructuring expenses through March 31, 2026, with the remaining nominal expense expected to be recognized in the second quarter of the year.
AMRN's Zacks Rank & Other Stocks to Consider
Amarin currently sports a Zacks Rank #1 (Strong Buy).
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have also narrowed from 79 cents to 78 cents. CSTL shares have lost 37.6% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have decreased from $3.01 to $3.00. Over the same period, EPS estimates for 2027 have plunged from $3.35 to $3.29. INDV shares have lost 4.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.82 to $2.87. Over the same period, EPS estimates for 2027 have surged from $3.20 to $3.25. CPRX shares have gained 21.1% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
Key Takeaways
Amarin Corporation (AMRN - Free Report) incurred an adjusted loss of 9 cents per share for the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported an adjusted loss of 45 cents per share in the year-ago quarter. Adjusted loss per share excluded stock-based compensation expense and restructuring expense.
Total revenues in the quarter were $45.1 million, beating the Zacks Consensus Estimate of $42 million. Revenues increased 7% from the year-ago quarter’s level, driven by higher partnered sales volume.
Year to date, shares of Amarin have risen 2.4% against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
AMRN's Q1 Earnings in Detail
Amarin’s top line comprises product revenues from its sole marketed drug, Vascepa, along with licensing and royalty revenues. Vascepa is approved as an adjunct to diet for the treatment of severe hypertriglyceridemia and to reduce cardiovascular risk in patients with persistently elevated triglycerides on statin therapy for LDL-C.
Net product revenues from Vascepa in the first quarter were $43.3 million, up 6% year over year. This metric beat the Zacks Consensus Estimate of $39.5 million.
U.S. product revenues from Vascepa were $35.6 million, consistent with the prior-year period.
Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $4.9 million, decreasing 9% from the year-ago quarter. This was due to the company’s transition to a fully partnered model with Recordati in the European market. However, Vazkepa sales increased 113% sequentially.
Revenues in the Rest of the World were $2.8 million.
Licensing and royalty revenues came in at $1.8 million in the first quarter, increasing 84% on a year-over-year basis due to higher in-market sales generated by international sales partners.
Selling, general and administrative expenses (excluding stock-based compensation expense) declined 41.3% year over year to $19.4 million.
Research and development expenses (excluding stock-based compensation expense) totaled $4.1 million, decreasing 9% on a year-over-year basis.
Amarin ended the quarter with cash and investments of $307.8 million compared with $302.6 million as of Dec. 31, 2025, and remained debt-free.
AMRN's Recent Key Developments
In 2025, Amarin signed an exclusive, long-term licensing and supply agreement with Italy-based pharmaceutical company Recordati to commercialize Vazkepa across 59 European countries. Recordati has already begun commercial activities in 10 countries, including a launch in Italy in the fourth quarter of 2025, and plans to gradually expand distribution across additional European markets over the coming years.
Under this fully partnered ex-U.S. model, management expects improved cost efficiency and sustained positive cash flow in 2026. The company has already delivered positive cash flow for two consecutive quarters through the first quarter of 2026.
Per management, with the transition now complete, reported European revenues will solely comprise supply shipments made to Recordati going forward.
Amarin remains on track to realize approximately $70 million in annual cost savings under the global restructuring program and has incurred the majority of the restructuring expenses through March 31, 2026, with the remaining nominal expense expected to be recognized in the second quarter of the year.
AMRN's Zacks Rank & Other Stocks to Consider
Amarin currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) ,currently sporting a Zacks Rank #1, and Indivior Pharmaceuticals (INDV - Free Report) and Catalyst Pharmaceuticals (CPRX - Free Report) , which carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have also narrowed from 79 cents to 78 cents. CSTL shares have lost 37.6% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have decreased from $3.01 to $3.00. Over the same period, EPS estimates for 2027 have plunged from $3.35 to $3.29. INDV shares have lost 4.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.82 to $2.87. Over the same period, EPS estimates for 2027 have surged from $3.20 to $3.25. CPRX shares have gained 21.1% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.